Sanofi partners with Revolution Medicines to develop SHP2 inhibitors for cancer treatment

Sanofi entered an agreement with Revolution Medicines to develop SHP2 inhibitors, including the latter's small-molecule drug RMC-4630, for patients with non-small-lung cancer and other tumour types carrying certain mutations, the companies reported Wednesday. Joanne Lager, head of oncology development at Sanofi, said the drugs "could provide a new way to treat patients with non-small-cell lung cancer and other cancers that have specific types of genetic mutations."

Under the deal, the drugmakers will jointly develop SHP2 inhibitors, with Revolution Medicines continuing to lead research and early clinical development, and Sanofi leading later development activities. The companies noted that the first clinical trials of RMC-4630 are expected to start in the second half.

As part of the agreement, Sanofi will make an upfront payment of $50 million to Revolution Medicines, with the French drugmaker covering R&D costs for the joint SHP2 programme. Revolution Medicines is eligible to receive more than $500 million in development and regulatory milestone payments, while the companies will enter into a 50/50 profit and loss share arrangement in the US. In addition, Revolution Medicines stands to receive a tiered royalty as high as the mid-double digits on sales outside the US.

To read more Top Story articles, click here.